Ivabradine Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
01/03/2022 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
R/0010 
Renewal of the marketing authorisation. 
16/12/2021 
14/02/2022 
SmPC, 
Labelling and 
PL 
Annex II and 
PL 
IA/0012 
A.7 - Administrative change - Deletion of 
06/01/2022 
manufacturing sites 
IA/0011 
A.7 - Administrative change - Deletion of 
20/10/2021 
n/a 
manufacturing sites 
IA/0009 
B.II.d.1.d - Change in the specification parameters 
27/07/2021 
n/a 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
IB/0008 
B.II.b.3.z - Change in the manufacturing process of 
15/03/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0007/G 
This was an application for a group of variations. 
06/11/2020 
n/a 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.c.1.z - Change in immediate packaging of the AS 
- Other variation 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0006 
B.II.b.3.z - Change in the manufacturing process of 
22/01/2020 
n/a 
the finished or intermediate product - Other variation 
Page 3/5 
 
 
 
 
 
 
 
 
 
IA/0005 
B.II.d.2.a - Change in test procedure for the finished 
20/11/2019 
n/a 
product - Minor changes to an approved test 
procedure 
IAIN/0004/G 
This was an application for a group of variations. 
13/02/2019 
04/02/2020 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
T/0003 
Transfer of Marketing Authorisation 
18/01/2019 
06/02/2019 
SmPC, 
Labelling and 
PL 
IAIN/0002 
B.II.b.2.c.1 - Change to importer, batch release 
05/04/2018 
n/a 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/03/2018 
06/02/2019 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 5/5 
 
 
 
 
 
 
 
 
